HPV-related disease | Reduction in cases of HPV-related diseases n(%): Routine plus catch-upa 9vHPV vs routine 9vHPV | Reduction in cases of HPV-related disease n(%): Routine 9vHPV vs screening only | Reduction in cases of HPV-related disease n(%): Routine plus catch-Upa 9vHPV vs screening only |
---|---|---|---|
Cervical cancer | 769 (3.4) | 19,880 (46.9) | 20,649 (48.7) |
CIN 1 | 121 (4.9) | 3968 (61.8) | 4089 (63.7) |
CIN 2/3 | 428 (4.6) | 13,766 (59.7) | 14,194 (61.5) |
Vaginal cancer | 2 (3.1) | 48 (38.4) | 50 (40.2) |
Vaginal intraepithelial neoplasia 2/3 | 2 (3.4) | 51 (43.6) | 54 (45.5) |
Vulvar cancer | 5 (3.0) | 92 (37.2) | 97 (39.1) |
Genital warts (female) | 6401 (5.4) | 306,673 (72.3) | 313,074 (73.8) |
Genital warts (male) | 10,090 (2.6) | 534,895 (58.2) | 544,985 (59.3) |
HPV 6/11-related CIN 1 | 20 (4.2) | 894 (65.3) | 914 (66.7) |
Anal cancer (female) | 55 (2.4) | 1087 (32.2) | 1142 (33.8) |
Anal cancer (male) | 42 (1.8) | 849 (27.1) | 891 (28.4) |
Reduction in vaccine-preventable disease costs, % (HKD) | 61,366,272 (2.1) | 884,053,918 (23.2) | 945,420,190 (24.8) |